ArticleBriefings in bioinformatics2025
Powerful gene network enrichment analysis and its application to severe COVID-19 gene network.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Understanding complex disease mechanisms requires research methods beyond individual gene analysis to capture the coordinated behavior of genes within regulatory networks. Traditional gene set enrichment approaches such as over-representation analysis and gene set enrichment analysis focus primarily on gene lists and often overlook the intricate network structures that control cellular processes. Although a gene network enrichment analysis strategy (GbNEA) has been proposed, this method assesses enrichment significance via phenotype permutation and the Kolmogorov-Smirnov test, which lowers statistical power and increases the computational burden due to repeated gene network re-estimation. To overcome these limitations, we developed a novel approach, powerful gene network enrichment analysis (PGNEA), which characterizes gene networks by integrating gene expression, regulatory effects, and hubness. PGNEA evaluates the enrichment of phenotype-specific gene networks by quantifying differences in gene activity patterns and assesses statistical significance by evaluating permutation of gene activity rather than phenotype permutation. This approach exhibits significantly enhanced computational efficiency and statistical sensitivity. We demonstrated the advantages of PGNEA through Monte Carlo simulations and applied it to whole-blood RNA-seq data obtained from the Japan COVID-19 Task Force. PGNEA successfully identified viral infection-related pathways enriched in severe COVID-19 gene networks, including those linked to "COVID-19," "HIV-1 infection," "Hepatitis B," "Influenza A," "Measles," and "Kaposi sarcoma-associated herpesvirus infection." Notably, key molecular markers such as PIK3, NF-B family members, FOXA, JUN, and CXCL8 were identified, with strong and consistent molecular interplays between CXCL8 and NFKBIA. These findings underscore the potential of PGNEA as an efficient tool for identifying biologically meaningful pathways and network-level mechanisms associated with various phenotypes, including severe viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.